← Leaderboards
Jeffrey T Holt
Vanderbilt University
$3,594,793
Attributed
$3,594,793
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $627.1K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$3,594,793 · 7
By mechanism
R01$1,660,117 · 2
R44$962,126 · 1
R42$606,979 · 1
R41$365,571 · 3
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Claire Edwards$1,226,539
- Paul E. Bock$13,099,087
- Susan Renee Opalenik$1,495,941
- Gillian Fitz$62,652
- Darrel L. Ellis$67,005
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchGene MutationMalignant Neoplasm Of OvaryMutationTissuesAffectProteinsInhibitor/AntagonistFamilyImmunohistochemistryAnimalsCancer PatientAntibodiesInheritedGenesFamily MemberHereditary Malignant NeoplasmBrca2 MutationClinical TrialsFundingBrca1 GeneBreastBaseBrca2 Gene
Grant awards (15)
IHC Test for BRCA1 Hereditary Ovarian Cancer$399,246
R44 · FY2012 · CA · contact PI
AFAP-110 as a cSrc activator in breast cancer$227,829
R01 · FY2012 · CA · contact PI
IHC Test for BRCA1 Hereditary Ovarian Cancer$399,246
R44 · FY2011 · CA · contact PI
BRCA2 Hereditary Ovarian Cancer Tissue Truncation Test$307,776
R42 · FY2010 · CA · contact PI
IHC Test for BRCA1 Hereditary Ovarian Cancer$163,634
R44 · FY2010 · CA · contact PI
BRCA2 Hereditary Ovarian Cancer Tissue Truncation Test$299,203
R42 · FY2009 · CA · contact PI
PARP Inhibitor Targeted Therapy for Breast Cancer$149,043
R41 · FY2008 · CA · contact PI
BRCA2 Hereditary Ovarian Cancer Tissue Truncation Test$161,679
R41 · FY2007 · CA · contact PI
Development of a BRCA Breast Cancer Diagnostic Test$54,849
R41 · FY2007 · CA · contact PI
Mechanisms of Carcinogenesis in BRCA2 Mutant Cells$229,577
R01 · FY2005 · CA
Mechanisms of Carcinogenesis in BRCA2 Mutant Cells$230,237
R01 · FY2004 · CA
Mechanisms of Carcinogenesis in BRCA2 Mutant Cells$265,263
R01 · FY2003 · CA
Mechanisms of Carcinogenesis in BRCA2 Mutant Cells$373,468
R01 · FY2002 · CA
Mechanisms of Carcinogenesis in BRCA2 Mutant Cells$32,253
R01 · FY2002 · CA
Mechanisms of Carcinogenesis in BRCA2 Mutant Cells$301,490
R01 · FY2001 · CA